The effects of PIKfyve inhibitor YM201636 on claudins and malignancy potential of nonsmall cell cancer cells

Authors : Eda DOGAN, Zekeriya DUZGUN, Zafer YİLDİRİM, Berrin OZDİL, Huseyin AKTUG, Vildan BOZOK CETİNTAS

Pages : 26-34

View : 16 | Download : 5

Publication Date : 2021-12-01

Article Type : Research Paper

Abstract :PIKfyve is an evolutionarily conserved lipid and protein kinase enzyme that has pleiotropic cellular functions. The aim of the present study was to investigate the effects of phosphatidylinositol-3-phosphate 5-kinase insert ignore into journalissuearticles values(PIKfyve); inhibitor, YM201636, on nonsmall cell lung cancer insert ignore into journalissuearticles values(NSCLC); cells growth, tumorigenicity, and claudin insert ignore into journalissuearticles values(CLDN); expressions. Three NSCLC cell lines insert ignore into journalissuearticles values(Calu-1, H1299 and HCC827); were used to compare the effects of YM201636. Cytotoxic effects of YM201636 were analysed using XTT assay. Malignancy potential of cells assesses with wound healing and soft agar colony-forming assays. mRNA and protein expressions of claudins were analysed by qRT-PCR and immunofluorescence staining. Our results revealed that YM201636 inhibited the proliferation and malignancy potential of Calu-1, H1299, and HCC827 cells in a dose-dependent manner. After YM201636 treatment CLDN1, -3 and -5 expressions increased significantly in HCC827 cells. CLDN3 and -5 expressions also significantly increased in Calu-1 cell line. YM201636 treatment significantly reduced the CLDN1 and increased the CLDN5 expression in H1299 cells. Immunofluorescence staining of CLDN1, -3 and -5 proteins showed a significant increase after YM201636 treatment. Besides, YM201636 induced EGFR mRNA expression in all NSCLC cell lines. Our results have shown that YM201636 inhibits tumorigenicity of NSCLC cells. Furthermore, estimated glomerular filtration rate insert ignore into journalissuearticles values(EGFR); pathway is important signalling involved in the regulation of claudins. Understanding the mechanisms of PIKfyve inhibitors may improve cancer treatment particularly for EGFR overactivated NSCLC.
Keywords : Claudin, epidermal growth factor receptor, nonsmall cell lung cancer, PIKfyve, YM201636